Abstract:Protein-protein interactions (PPIs) represent promising drug targets of broad-spectrum therapeutic interests due to their critical implications in both health and disease circumstances. Hence, they are widely accepted as the Holy Grail of drug development. Historically, PPIs were rendered "undruggable" for their large, flat, and pocket-less structures. Current attempts to drug these "intractable" targets include orthosteric and allosteric methodologies. Previous efforts employing orthosteric approaches like protein therapeutics and orthosteric small molecules frequently suffered from poor performance caused by the difficulties in directly targeting PPI interfaces. As structural biology progresses rapidly, allosteric modulators, which direct to the allosteric regulatory sites remote to the PPI surfaces, have gradually established as a potential solution. Allosteric pockets are topologically distal from the PPI orthosteric sites, and their ligands do not need to compete with the PPI partners, which helps to improve the physiochemical and pharmacological properties of allosteric PPI modulators. Thus, exploiting allostery to tailor PPIs is regarded as a tempting strategy in future PPI drug discovery. Here, we provide a comprehensive review of our representative achievements along the way we utilize allosteric effects to tame the difficult PPI systems into druggable targets. Importantly, we provide an in-depth mechanistic analysis of this success, which will be instructive to future related lead optimizations and drug design. Finally, we discuss the current challenges in allosteric PPI drug discovery. Their solutions as well as future perspectives are also presented.

The Chemical Diversity and Structure-Based Discovery of Allosteric Modulators for the PIF-pocket of Protein Kinase PDK1

Development of small-molecule inhibitors that target PI3Kβ

Structure-based drug design and molecular dynamics studies of an allosteric modulator targeting the protein–protein interaction site of PDK1

Development of small-molecule inhibitors that target PI3K13

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Recent advances in pyruvate dehydrogenase kinase inhibitors: Structures, inhibitory mechanisms and biological activities

Recent Advances in the Development of Allosteric Protein Tyrosine Phosphatase Inhibitors for Drug Discovery.

Modulation of the substrate specificity of the kinase PDK1 by distinct conformations of the full-length protein

Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B

Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments

New Promise and Opportunities for Allosteric Kinase Inhibitors

Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta)

Emerging Roles of Allosteric Modulators in the Regulation of Protein‐protein Interactions (ppis): A New Paradigm for PPI Drug Discovery

[Targeting the Substrate Binding Domain of Polo-Like Kinase 1: Advances in the Study of PBD1 Inhibitors].

Docking of Protein Kinase B Inhibitors: Implications in the Structure-Based Optimization of A Novel Scaffold

Allosteric Modulators of Protein-Protein Interactions (PPIs).

Targeting the PDK/PDH Axis to Reverse Metabolic Abnormalities by Structure-Based Virtual Screening with in Vitro and in Vivo Experiments.

Dynamics of Post-Translational Modification Inspires Drug Design in the Kinase Family

An Isoform-Selective, Small-Molecule Inhibitor Targets the Autoregulatory Mechanism of p21-Activated Kinase